The ScHARR Technology Assessment Group (ScHARR-TAG) is part of a wider collaboration who undertake reviews for National Institute for Health and Care Excellence (NICE) and National Institute for Health Research (NIHR).

Work for NICE

Multiple Technology Appraisals (MTAs)

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111].

Non Bisphospenates for Osteoporosis. Review of (TA160, TA161, TA204) [ID901].

Single Technology Appraisals (STAs)

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]

Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].

Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507].

Clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions [ID1150].

Pentosan polysulfate sodium for treating bladder pain syndrome [ID1364].

Olaparib for maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after response to initial platinum-based chemotherapy [ID1124].

Pembrolizumab with carboplatin and paclitaxel for untreated squamous non-small-cell lung cancer [ID1306].

Sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].

Blinatumomab for treating B-precursor, minimal residual remission acute lymphoblastic leukaemia [ID1036].

Nusinersen for treating infant or child spinal muscular atrophy [ID1069].

Regorafenib after sorafenib, for treating unresectable hepatocellular carcinoma [ID991].

Sarilumab after TNFnhibitors for treating active rheumatoid arthritis [ID994].

Cx601 for treating complex perianal fistula in non-active or mildly-active luminal Crohn’s disease [ID960].

Diagnostic Assessment Reports (DARs)

The EndoPredict multigene test for guiding therapy decisions in breast cancer management 16/30/03.

Fast Track Assessments (FTAs)

Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable [ID1209].

Golimumab after NSAIDs for severe, active, non-radiographic, Axial spondyloarthritis [ID903].

Highly Specialised Technologies (HSTs)

Volanesorsen for treating familial chylomicronaemia syndrome [ID1326].

Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279].

Recombinant human alpha-mannosidase for treating alpha-mannosidosis [ID800].

Work for NIHR


Modelling approaches for site-agnostic cancer drugs to inform NICE appraisal [NIHR127852]

Review on patient safety and reduction of risk of transmission of Creutzfeldt-Jakob disease (CJD) [17/48/01].

Short Reports

None currently.

For additional topics in the fields see the right hand side.